Evaluation of a Novel Maghemite Hybrid Nanocarrier for MR Imaging (Pilot Study)

The aim of this study was to investigate Mag 102-6, a maghemite hybrid drug nanocarrier, as a potential T2 contrast agent (CA) for magnetic resonance imaging (MRI). Samples of agar gel mixed with different Fe concentrations of Mag 102-6 were measured at laboratory temperature for relaxivity r2 determination in 9.4 T. The results were compared with commercial CA FeraSpin XXL measured in the same arrangement. In addition, the r2 of Mag 102-6 in saline solution at physiological temperature 37.7 degree Celsius was measured. MRI was performed with four mice using a 9.4T NMR scanner before, and up to 24 h post-injection (p) of Mag 102-6 (dose 5 mg Fe kg-1).